Clinical Trial Update: Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating continuous 24-hour IV mithramycin for thoracic malignancies with pleuropulmonary metastases was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms
• Lung Neoplasms
• Mesothelioma
• Neoplasms Germ Cell and Embryonal
• Thymus Neoplasms

Drugs mentioned

• Mithramycin (mithramycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Esophageal Neoplasms, Lung Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-05